Charles River Laboratories International, Inc. (NYSE:CRL) Receives Average Recommendation of “Moderate Buy” from Brokerages

Charles River Laboratories International, Inc. (NYSE:CRL) has received an average recommendation of “Moderate Buy” from the eighteen ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation, ten have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $190.8571.

Several research firms have issued reports on CRL. Morgan Stanley set a $185.00 price objective on Charles River Laboratories International in a research note on Monday. JPMorgan Chase & Co. increased their price objective on shares of Charles River Laboratories International from $160.00 to $165.00 and gave the stock a “neutral” rating in a report on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, October 8th. Wall Street Zen cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Baird R W upgraded shares of Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 6th.

Hedge Funds Weigh In On Charles River Laboratories International

Several large investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in Charles River Laboratories International by 0.5% in the third quarter. Vanguard Group Inc. now owns 5,839,743 shares of the medical research company’s stock worth $913,686,000 after purchasing an additional 27,989 shares during the period. Wellington Management Group LLP grew its position in shares of Charles River Laboratories International by 5.1% during the 1st quarter. Wellington Management Group LLP now owns 4,285,012 shares of the medical research company’s stock worth $644,980,000 after buying an additional 208,586 shares during the period. Allspring Global Investments Holdings LLC raised its stake in shares of Charles River Laboratories International by 29.1% during the second quarter. Allspring Global Investments Holdings LLC now owns 2,291,126 shares of the medical research company’s stock worth $353,750,000 after buying an additional 516,521 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC raised its stake in shares of Charles River Laboratories International by 8.0% during the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,950,273 shares of the medical research company’s stock worth $293,555,000 after buying an additional 144,732 shares during the last quarter. Finally, Ariel Investments LLC lifted its holdings in Charles River Laboratories International by 28.6% in the second quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company’s stock valued at $214,751,000 after buying an additional 314,572 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

Shares of Charles River Laboratories International stock opened at $184.88 on Thursday. The firm has a market cap of $9.10 billion, a P/E ratio of -118.51, a price-to-earnings-growth ratio of 6.22 and a beta of 1.63. The firm’s 50-day simple moving average is $173.35 and its 200-day simple moving average is $160.98. Charles River Laboratories International has a twelve month low of $91.86 and a twelve month high of $202.72. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.10 and a current ratio of 1.37.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, beating analysts’ consensus estimates of $2.32 by $0.11. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $990.43 million. During the same period in the previous year, the business earned $2.59 earnings per share. The company’s quarterly revenue was down .5% on a year-over-year basis. As a group, research analysts expect that Charles River Laboratories International will post 9.36 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).